• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2003 Fiscal Year Final Research Report Summary

Basic study to establish molecular diagnosis and gene therapy for anticancer drug-resistant cancer cells

Research Project

Project/Area Number 13470353
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Research Field Obstetrics and gynecology
Research InstitutionWakayama Medical University

Principal Investigator

TANAKA Tetsuji  Wakayama Medical University, Medical School, Associate Professor, 医学部, 助教授 (80275255)

Co-Investigator(Kenkyū-buntansha) OTANI Naoko  Wakayama Medical University, Medical School, Assistant Staff, 医学部, 助手 (80343424)
OTANI Tsutomu  Wakayama Medical University, Medical School, Assistant Staff, 医学部, 助手 (90343425)
UMESAKI Naohiko  Wakayama Medical University, Medical School, Professor, 医学部, 教授 (20106339)
TANAKA Kazuharu  Wakayama Medical University, Medical School, Assistant Staff, 医学部, 助手
YAGI Shigetaka  Wakayama Medical University, Medical School, Assistant Staff, 医学部, 助手
Project Period (FY) 2001 – 2003
KeywordsUterine Cancer / Ovarian Cancer / Multidrug-resistance gene / Anti-cancer drug-resistance
Research Abstract

(1)Cellular and molecular characterization of anticancer drug-resistant cancer cells : Using more than 100 anticancer drug-resistant subclones derived from human uterine and ovarian carcinomas, their drug-sensitivities were quantitatively evaluated and compared to the results of mRNA expression profiling of the resistant subclones. In this study, we have first found some relationships of death-associated protein kinase (DAPK) and anticancer-drug sensitivities of cancer cells. Demethylation of uterine cancer cells induced DAPK expression and restored their SN38-sensitivity. Demethylation of SN38-resistant cells restored SN38-sensitivity while demethylation of CDDP-resistant cells did not affect their CDDP-sensitivities.
(2)mRNA expression profiling of the drug-resistant subclones : cDNA microarray analyses revealed mRNA expression profiling of the drug-resistant subclones. Especially, c-myc mRNA expressions were significantly suppressed in many anti-cancer drug-resistant subclones.
(3)Suppression of mRNA expression may disclose candidate genes of drug-sensitivity-regulating molecules : By using siRNA procedure, we have been discovering candidate genes of drug-sensitivity-regulating molecules. Relationship of STAT3 expression and anticancer drug-sensitivity has been investigated.
(4)Basic study on gene therapy for drug-resistant cancer cells : Recently we have identified that growth-inhibitory signals of TGF-beta1 can be completely inhibited by activin A, indicating increased activin-A in endometrial adenocarcinoma indirectly enhance cell proliferation of the cancer cells. As targets for gene therapy, therefore ; we are investigating the regulatory factors that stimulate activin A production in cancer tissues.
(5)Basic study for concurrent chemoradiation : In in vitro experiments with cervical SCC cells, we have found optimal combination of anticancer drugs with radiotherapy.

  • Research Products

    (12 results)

All Other

All Publications (12 results)

  • [Publications] Bai T, Tanaka T, et al.: "Reduced expression of death-associated protein kinase in human uterine and ovarian carcinoma cells."Oncology Reports. 11. 661-665 (2004)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Tanaka T, et al.: "Growth-inhibitory signals by activin A do not affect anticancer drug-sensitivity and acquired multi-drug-resistance in human ovarian endometrioid adenocarcinoma OVK-18 cells."Oncology Reports. 11. 667-671 (2004)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Tanaka T, et al.: "Activin A inhibits growth-inhibitory signals by TGF-β1 in differentiated human endometrial adenocarcinoma cells."Oncology Reports. 11. 875-879 (2004)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Tanaka T, et al.: "Expression and function of activin receptors in human endometrial adenocarcinoma cells."Int J Oncol. 23. 657-663 (2003)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Tanaka T, Umesaki N: "Fas antigen (CD95) mediates cell survival signals to regulate functional cellular subpopulations in normal human endometrial stromal cells."Int J Mol Med. 11. 757-762 (2003)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Tanaka T: "Establishment and characterization of the SN38-resistant sublines from human cervical SCC."J Jpn Soc Gynecol Oncol. 20. 210-215 (2002)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Bai T, Tanaka T, et al.: "Reduced expression of death-associated protein kinase in human uterine and ovarian carcinoma cells"Oncology Reports. 11. 661-665 (2004)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tanaka T, et al.: "Growth-inhibitory signals by activin A do not affect anticancer drug-sensitivity and acquired multi-drug-resistance in human ovarian endometrioid adenocarcinoma OVK-18 cells"Oncology Reports. 11. 667-671 (2004)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tanaka T, et al.: "Activin A inhibits growth-inhibitory signals by TGF-β1 in differentiated human endometrial adenocarcinoma cells"Oncology Reports. 11. 875-879 (2004)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tanaka T, et al.: "Expression and function of activin receptors in human endometrial adenocarcinoma cells"International Journal of Oncology. 23. 657-663 (2003)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tanaka T, Umesaki N: "Fas antigen (CD95) mediates cell survival signals to regulate functional cellular subpopulations in normal human endometrial stromal cells"International Journal of Molecular Medicine. 11. 757-762 (2003)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tanaka T: "Establishment and Characterization of the SN38-Resistant Sublines from Human Cervical SCC"J Jpn Soc Gynecol Oncol. 20. 210-215 (2002)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2005-04-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi